| چکیده انگلیسی مقاله |
Background: Breast cancer (BC) counts for half of the excess risk of second cancer after Hodgkin Lymphoma (HL), but evidence about the clinical and pathological features of these cancers is lacking. The aim of this study was to evaluate whether these secondary BCs have distinctive characteristics compared to sporadic ones. Methods: This is a case-control study comparing patients who developed BC after receiving treatment for HL with an age-matched cohort of non-irradiated patients. All the cases were treated at the Veneto Institute of Oncology (Padua, Italy) between 2002 and 2017. We analyzed the clinical and pathologic features of BCs and compared treatment modalities using Chi-squared tests. Kaplan-Meier survival analyses were conducted to investigate overall and disease-free survival in the two groups. Results: 35 patients who were treated for HL and subsequently developed BCs were identified. BC occurred after a mean interval of 19.65 years (SD=10.08 years) from the HD diagnosis. 4 of the patients treated for HL (11.4%) had a bilateral presentation. 80% of the cases and 63% of the controls were ER+/HER- (p=0.516), while 20% of the HL group and 5.7% of the sporadic group were ER- /HER- (p=0.116). Ipsilateral BC recurrence (17.1% vs 8.6% in the sporadic BC group, p=0.346) and death events were more frequent in the HL group (11.4% vs 5.7% in the sporadic BC group, p=0.433), with a mean follow-up of 70 months (standard deviation=42.8months). Conclusions: Our data show that BC arising after HL often presented with bilateral localization, aggressive biological profiles, and had high recurrence rates. Dedicated treatment modalities should be considered and evaluated in a multidisciplinary setting. |
| نویسندگان مقاله |
| Francesco Milardi
General Surgery, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35121 Padua, Italy
| Silvia Michieletto
Breast Surgery Unit, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy.
| Fernando Bozza
Breast Surgery Unit, Department of Surgery, Villa Salus Hospital, Venice, Italy.
| Lisa Rigato
Breast Surgery Unit, Department of Surgery, Villa Salus Hospital, Venice, Italy.
| Tania Saibene
Breast Surgery Unit, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy
| Matteo Cagol
Breast Surgery Unit, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy
| Massimo Ferrucci
Breast Surgery Unit, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy
| Daniele Passeri
General Surgery, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35121 Padua, Italy
| Mariacristina Toffanin
Breast Surgery Unit, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy
| Tajna Kraljic
Breast Surgery Unit, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy
| Alberto Marchet
Breast Surgery Unit, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy
| Laura Evangelista
IRCCS Humanitas Research Hospital, Rozzano,
|